Collectively, our findings suggest that the underlying cause of osteoporosis and skeletal dysplasia in patients with pathogenic variants in SGMS2 is not a reduced cellular capacity to synthesize sphingomyelin but rather a perturbation in sphingomyelin metabolism at the plasma membrane. The gene discussed is SGMS2; the disease is skeletal dysplasia.